This Activin A Receptor Type IB/ALK-4 antibody is un-conjugated
Flow Cytometry (FACS), Western Blotting (WB)
This antibody is purified through a protein A column, followed by peptide affinity purification.
This Activin A Receptor Type IB (ACVR1B) antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 134-164 amino acids from the Central region of human Activin A Receptor Type IB (ACVR1B).
ACVR1B, alk4, skr2, alk-4, xalk4, actrib, acvrlk4, DKFZp469A1614, 6820432J04, ActR-IB, ActRIB, Acvrlk4, Alk4, SKR2, ACTRIB, ACVRLK4, ALK4, Skr2, axis, taram-a, tarama, wu:fb75f01, activin A receptor type 1B, Activin receptor type-1B, activin A receptor, type IB, activin A receptor, type 1B, activin A receptor type 1Ba, ACVR1B, acvr1b, acv1b, Acvr1b, acvr1ba
Activins are dimeric growth and differentiation factors which belong to the transforming growth factor-beta (TGF-beta) superfamily of structurally related signaling proteins. Activins signal through a heteromeric complex of receptor serine kinases which include at least two type I (I and IB) and two type II (II and IIB) receptors. These receptors are all transmembrane proteins, composed of a ligand-binding extracellular domain with a cysteine-rich region, a transmembrane domain, and a cytoplasmic domain with predicted serine/threonine specificity. Type I receptors are essential for signaling, and type II receptors are required for binding ligands and for expression of type I receptors. Type I and II receptors form a stable complex after ligand binding, resulting in phosphorylation of type I receptors by type II receptors. The gene for ACVR1B (activin A type IB receptor) is composed of 11 exons. Alternative splicing and alternative polyadenylation result in 3 fully described transcript variants. The mRNA expression of variants 1, 2, and 3 is confirmed, and a potential fourth variant contains an alternative exon 8 and lacks exons 9 through 11, but its mRNA expression has not been confirmed.